Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks

HIV Clinical Trials
Dushyantha JayaweeraDaniel W Seekins

Abstract

This study evaluated the long-term efficacy, safety, adherence, and quality of life (QoL) of a once-daily efavirenz-based antiretroviral regimen in two 96-week prospective open-label single-arm studies of treatment-naïve HIV-1-infected patients. Patients received once-daily efavirenz 600 mg and lamivudine 300 mg with either enteric-coated didanosine 400 mg (Daily Antiretroviral Therapy trial [DART] I) or extended-release stavudine 100 mg (DART II). The primary efficacy outcome measure was HIV RNA <400 copies/mL at Week 48. In an intent-to-treat (ITT) analysis, HIV RNA level <400 (<50) copies/mL was reached by 82%(80%) and 74% (72%) of patients at Week 48 in DART I and II. At Week 96, the corresponding values were 74% (68%) and 55% (54%), respectively. Both regimens were well tolerated. There were no discontinuations for virologic failure. Medication adherence assessed by pill counts was above 80% in 90% of the patients in DART I and more than 80% of patients in DART II. Treatment produced a significant improvement in overall QoL. Once-daily efavirenz-based antiretroviral therapy was effective, durable, and well tolerated. In this study, a high level of adherence was achieved with improvement in overall QoL.

References

Aug 1, 1997·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·A W WuF E Malitz
Jul 6, 2000·Annals of Internal Medicine·D L PatersonN Singh
Feb 8, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·J A Bartlett
May 10, 2003·AIDS Patient Care and STDs·Margaret Chesney
Oct 3, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ajay K SethiJoel E Gallant
Oct 16, 2004·Expert Review of Anti-infective Therapy·Claude Fortin, Veronique Joly
Dec 23, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Franco MaggioloFredy Suter
Aug 11, 2005·Current HIV/AIDS Reports·Gregory M LucasLaura W Cheever
Jan 27, 2007·AIDS·Sigrid C J M VervoortMieke H F Grypdonck
Feb 1, 2007·AIDS Research and Human Retroviruses·Xiuqiong BiShinichi Oka
Feb 6, 2007·The Journal of the Association of Nurses in AIDS Care : JANAC·Anne M Battaglioli-DeNero
Feb 16, 2008·AIDS Research and Human Retroviruses·Jesús SantosUNKNOWN Grupo Andaluz Para el Estudio de las Enfermedades Infecciosas (GAEI)
May 16, 2008·The New England Journal of Medicine·Sharon A RiddlerUNKNOWN AIDS Clinical Trials Group Study A5142 Team

❮ Previous
Next ❯

Citations

Jun 30, 2011·AIDS Care·Bach Xuan TranThao Huong Nguyen
Sep 30, 2010·AIDS and Behavior·Janet RaboudMona R Loutfy
Oct 10, 2012·Expert Opinion on Pharmacotherapy·Nitipong PermpalungKiat Ruxrungtham
Mar 21, 2013·Expert Opinion on Pharmacotherapy·Ma Gracia MateoPere Domingo
Nov 3, 2012·Health and Quality of Life Outcomes·Bach Xuan TranLong Thanh Nguyen
Oct 22, 2014·Journal of the International Association of Providers of AIDS Care·Sarah J TennantP Brandon Bookstaver
Jun 8, 2017·PloS One·Leonard EmurenUNKNOWN Infectious Disease Clinical Research Program HIV Working Group
Dec 17, 2014·Nursing & Health Sciences·Xianhong LiAnn Bartley Williams

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved